Pulocimab
- Generic Name
- Pulocimab
A Study of AK104/Placebo Plus AK109/Placebo And Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcinoma
Phase 3
Recruiting
- Conditions
- Gastric and Gastroesophageal Junction Adenocarcinoma
- Interventions
- First Posted Date
- 2024-04-02
- Last Posted Date
- 2024-06-24
- Lead Sponsor
- Akeso
- Target Recruit Count
- 506
- Registration Number
- NCT06341335
- Locations
- 🇨🇳
Peking University Cancer Hospital & Institute, Beijing, China
A Study of Anti-VEGFR2 AK109 in Subjects With Advanced Solid Tumors
- First Posted Date
- 2020-09-14
- Last Posted Date
- 2023-02-23
- Lead Sponsor
- Akeso
- Target Recruit Count
- 40
- Registration Number
- NCT04547205
- Locations
- 🇨🇳
The First Affiliated Hospital of Medicine College, Zhejiang University, Hangzhou, Zhejiang, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath